In one paragraphArticle in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Thamires Quadros FroesCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0001-7951-7560 Temitayo Omowumi Alegbejo PriceCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0002-8750-0635 Bruna Fleck GodoiCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0002-5910-0511 Miguel Menezes VaidergornCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0003-2343-2888 Thiago Dos SantosCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0001-7908-8604 Pedro Ivo Palacio LeiteCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.
Daniel Gedder SilvaCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0001-8879-456X Aline Dias da PurificaçãoCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0002-3127-7585 Leonardo LochDepartamento de Microbiologia Imunobiologia e Parasitologia, Disciplina de Biologia Celular, Universidade Federal de São Paulo, R. Pedro de Toledo 669 6A, Vila Clementino, São Paulo, SP 04039032, Brasil.
Sergio SchenkmanDepartamento de Microbiologia Imunobiologia e Parasitologia, Disciplina de Biologia Celular, Universidade Federal de São Paulo, R. Pedro de Toledo 669 6A, Vila Clementino, São Paulo, SP 04039032, Brasil.ORCID 0000-0001-9353-8480 Jadel M KratzDrugs for Neglected Diseases initiative (DNDi) Latin America, Rio de Janeiro, SP 20010-020, Brazil.ORCID 0000-0002-7681-8234 Flavio da Silva EmeryCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0002-8652-7123 Maria Cristina NonatoCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID 0000-0002-4916-1505 Funding
Validation of Trypanosoma cruzi dihydroorotate dehydrogenase as a drug target for Chagas´disease.R01AI160379 · NIAID · UNIVERSITY OF SAO PAULO · PI EMERY, FLAVIO DA SILVA, NONATO, MARIA CRISTINA · 2021 to 2025
$659kNIAID NIH HHS R01 AI160379
6 · The paper itselfAbstract
Covalent drug design applied to parasite proteins enables selective therapies by targeting nucleophilic residues of macromolecules. We present the first covalent inhibitors of
Indexed as
Antiprotozoal AgentsBarbituratesEnzyme InhibitorsLeishmania braziliensisOxidoreductases Acting on CH-CH Group DonorsCatalytic DomainCrystallography, X-RayDihydroorotate DehydrogenaseHumansModels, MolecularStructure-Activity RelationshipTHP-1 CellsAntiprotozoal AgentsBarbituratesbarbituric acidDihydroorotate DehydrogenaseEnzyme InhibitorsOxidoreductases Acting on CH-CH Group Donors
Identifiers
PMID40658390
PMCPMC12481576
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390